Highlights
• Phylogenetically diverse bacteria elicit C9orf72-dependent macrophage cytokine release
• Glycogen biosynthesis distinguishes commensals that elicit C9orf72-dependent inflammation
• Neural inflammation can be mitigated therapeutically by targeting glycogen in the gut
• Inflammatory forms of glycogen are enriched in the gut of ALS/FTD patients
Summary
Gut dysbiosis and neural inflammation occur in patients with amyotrophic lateral sclerosis (ALS), including those with a causal mutation in chromosome 9 open reading frame 72 (C9ORF72). How gut commensals interact with common ALS genotypes to impart risk of neural degeneration remains unclear.
Here, we identify 10 phylogenetically diverse bacterial strains that promote cytokine release in a C9orf72-dependent manner. Metatranscriptomics implicated the glycogen biosynthesis pathway as a driver of inflammation. Colonization of germ-free C9orf72-deficient mice with Parabacteroides merdae that produced inflammatory glycogen enhanced monocytosis, blood-brain barrier breakdown, and T cell infiltration into the central nervous system. Enzymatic digestion of glycogen in the gut promoted survival of C9orf72-deficient mice and dampened microglial reactivity in the brain.
A survey of human fecal samples demonstrated that inflammatory forms of glycogen were present in gut contents from 15/22 patients with ALS, 1/1 patient with C9ORF72 frontotemporal dementia (FTD), and 4/12 healthy controls.
Together, the results of this work identify bacterial glycogen as a modifiable mediator of immune homeostasis in the gut and brain.
